

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.  
Follow the sample format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE		
Daniel R. Wilson, MD, PhD	<i>Professor &amp; Chairman of Psychiatry Professor of Anthropology</i>		
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Yale, New Haven, CT, USA	BA	1979	<i>Anthropology</i>
Iowa, Iowa City, Iowa, USA	MD	1983	<i>Medicine</i>
Harvard, Boston, MA, USA	ABPN	1987	<i>Psychiatry Residency</i>
Cambridge, Cambridge, UK	PhD	1998	<i>Anthropology</i>

**NOTE:** The Biographical Sketch may not exceed four pages. Items A and B (together) may not exceed two of the four-page limit. Follow the formats and instructions on the attached sample.

**A. Positions and Honors.** List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

### Positions

1987-94 <i>Instructor in Psychiatry</i> 1987-92 <i>Psychiatrist-in-Charge, Psychosis Unit</i> 1992-93 <i>Rotary Visiting Scholar in Psychiatry</i> 1993-98 <i>Associate Professor of Psychiatry</i> 1998-00 <i>Professor of Psychiatry</i> 1993-00 <i>Chief Clinical Officer</i> 1998-00 <i>Statewide Chief Clinical Officer</i> 2000- <i>Professor &amp; Chairman of Psychiatry</i> 2000- <i>Professor of Anthropology</i>	Harvard Medical School, Boston, Massachusetts, USA McLean Hospital, Belmont, Massachusetts, USA University of Cambridge, Cambridge, UK University of Cincinnati, Cincinnati, Ohio, USA University of Cincinnati, Cincinnati, Ohio, USA ODMH-The Lewis Center, Cincinnati, Ohio ODMH-Statewide Intensive & Special Services, Ohio Creighton University, Omaha, Nebraska, USA Creighton University, Omaha, Nebraska, USA
---	--

### Selected Honors

1978-79 <i>Scholar of the House</i> 1982-83 <i>Rock Sleyster Scholar</i> 1983 <i>Margaret F. Huston Award</i> 1985-87 <i>Burroughs Wellcome Fellow</i> 1992-93 <i>Foundation Scholar</i> 1992-93 <i>Visiting Fellow</i> 1993 <i>Life Elector</i> 1994 <i>APA - National Exemplar Award</i> 1995 <i>NAMI National Award</i> 1995 <i>Life Fellow</i> 1995-96 <i>Mental Health Executive Program Scholar</i> 1997- <i>Overseas Fellow</i> 1998 <i>Life Member</i> 2000 <i>NAMI-Ohio Award of Excellence</i> 2001 <i>Distinguished Professor</i> 2002 <i>Best Psychiatrists in America</i> 2003- <i>Best Doctors in America</i> 2004 <i>Nancy C.A. Roeske, M.D., Award</i> 2005 <i>First Annual Irma Bland, M.D., Award</i> 2005 <i>Distinguished CME Faculty Award</i> 2006- <i>Alpha Omega Alpha - Life Member</i> 2006- <i>Who's Who in America</i> 2006- <i>America's Top Doctors</i>	Yale College American Medical Association University of Iowa American Psychiatric Association Rotary International Clare Hall, Cambridge, England Clare Hall, Cambridge, England Multi-Disciplinary Training ( <i>ODMH-Lewis Center</i> ) Multi-Disciplinary Training ( <i>ODMH-Lewis Center</i> ) American Board of Forensic Medicine Case Western Reserve University Weatherhead School of Management & School of Medicine Royal Anthropological Institute International Society of Police Surgeons Lewis Center -- Best Psychiatric Facility in Ohio" Janssen Pharmaceutica ( <i>on behalf of Creighton</i> ) Consumer Advisory Board Best Doctors Council American Psychiatric Association American Psychiatric Association Creighton University National Medical Honor Society Marquis Castle Connolly Medical
---	---

## Government Advisory Committees

US Department of Health & Human Services: National Institutes of Health (NIH): Substance Abuse & Mental Health Services Administration (SAMHSA); Center for Mental Health Services (CMHS): *Knowledge Development Standing Committee*

2000- *Initial Program Initial Review Panels*

1. SM 01-011 Treatment for Women in Public Housing & Services for Homeless Mothers Transitioning from Welfare to Work
2. SM 02-003 Community Action Grants for Service Systems Change
3. SM 03-004 State Training and Evaluation of Evidence-Based Practices
4. SM 04-007 Alternatives to Restraint and Seclusion
5. SM 03-003 State Training and Evaluation of Evidence-Based Practices

US Department of Health & Human Services: National Institutes of Health (NIH): National Institutes of Health: Addictions and Sleep Disorders (NPAS) Review Committee: 2005- *Study Section Special Review Panel:*

1. Neural Basis of Psychopathology

2002- *Nebraska HHS* Rural Health Advisory Committee (*ex officio*) & Region Six Steering Committee

2004- *Nebraska Unicameral* Legislative Oversight Commission for Behavioral Health Reform

2000- *Nebraska-Western Iowa VAMC* Dean's Committee & Mental Health Advisory Committee

## B. Selected peer-reviewed publications. (From some 200 papers, chapters and abstracts)

1. **Wilson, DR**; Cadoret, RJ; Widmer, R. *Somatic symptoms: A major feature of depression in a family practice.* J Aff D, 1983; 5:199-207
2. **Wilson, DR**; Cadoret, RJ. *Somatization among depressed patients in industrial nations.* Am J Psychi, 1983; 140: 1103-1104
3. **Wilson, DR. *A review of ethnopsychiatric studies of depression.* J J Psychi, 1987; 5(1): 41-53**
4. **Wilson, DR**; Cadoret, RJ; Widmer, R. *Anxiety in family practice.* J Aff D, 1987; 12: 179-83
5. **Wilson, DR. *Somatization.* Am J Psychi, 1989; 146: 410**
6. **Wilson, DR. *Evolutionary epidemiology.* Acta Biotheoretica, 1992; 40:87-89**
7. Freeman, P; **Wilson, DR**; Sierles, FS. *Psychopathology*, in Behavioral science for medical students, Sierles, FS (ed), Williams and Wilkins, Baltimore, MD, 1993
8. **Wilson, DR. *Evolutionary epidemiology & darwinian selection.* Clin Psych Quart 1993; 16: 3-6**
9. **Wilson, DR. *Evolutionary epidemiology: darwinian theory in the service of medicine and psychiatry.* Acta Biotheoretica, 1993; 41: 205-218**
10. **Wilson, DR. *The darwinian roots of human neurosis.* Acta Biotheoretica, 1994; 42: 49-62**
11. **Wilson, DR. *Evolutionary epidemiology.* J Int Psych, 1994; V10:1:6-12**
12. Keck, PE; **Wilson, DR**; Strakowski, SM; *et alia.* *Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder & psychotic mood disorder.* J Clin Psychi, 1995 56:10
13. Buckley, PF; **Wilson, DR**: A comparison of single daily dose and twice daily dose of risperidone in the treatment of schizophrenia. New Research in Mental Health, ODMH V12, 1996; 370-373
14. **Wilson, DR. *Evolutionary epidemiology*, in The Maladapted Mind: Classic papers in evolutionary psychopathology, Baron-Cohen, S (ed), Psychology Press, London, UK, 1997**
15. **Wilson, DR. *Court-authorized medication for incompetent patients*, in New Directions for Mental Health Services: Can mandatory treatment be therapeutic?, pp. 73-80, Munetz, M (ed), Jossey-Bass, San Francisco, CA, 1997**
16. **Wilson, DR. *Evolutionary epidemiology and manic-depression.* Br J Med Psychol, 1998; V71, 4/12: 375-396**
17. Hammond, C; Pierson, JF; Grande, T; Munetz, M; Wilson, D; Pathak, D. *An economic evaluation of risperidone in outpatients.* Annals of Pharmacotherapy 33(11):1160-6, 1999
18. **Wilson, DR. *Human Population Structure: Malthusian malignancy.* Anthropology Today V15:6: 24, 1999**
19. **Wilson, DR. *Gender vs. sex.* JAMA V284 (23) 2000; 2997-2998**
20. **Wilson, DR**; Sarkar, N; D'Souza, L; *et alia.* *Diabetogenesis and ketoacidosis with novel antipsychotics.* New Research in Mental Health, ODMH V14, 2000; 421-423
21. **Wilson, DR**; D'Souza, L; Newman, M; Nasrallah, H. *Prolactinemia in patients treated with olanzapine.* New Research in Mental Health, ODMH V14, 2000; 415-420
22. Hammond, C; **Wilson, DR**; Pierson, JF; *et alia.* *The pharmacoeconomics of risperidone: a naturalistic study.* New Research in Mental Health, ODMH V15, 2000
23. **Wilson, DR. *Is depression an adaptation? (letter).* Arch Gen Psychi V 58 (11); 2001**
24. **Wilson, DR**; Sarkar, N; D'Souza, L. *New onset diabetes and ketoacidosis with novel antipsychotics.* Schiz Res 59(1):1-6; 2003
25. Bakker, C; Gardner, R; Koliatsos, V; Kerbeshian, J; Looney, JG; Sutton, B; Swann, A; Verhulst, J; Wagner, KD; Wamboldt, F; **Wilson, DR. *The social brain: A unifying foundation for psychiatry.* Acad. Psychiatry 2002; 26: 219**
26. Klein, JR; **Wilson, DR. *Psychiatric consultation & testimony in legal proceedings.* Nebraska Lawyer; 2003; 6: 12-16**
27. **Wilson, DR. *Commentary: Schizophrenia as one extreme of a sexually selected fitness indicator.* Schiz Res 59(1); 2004;1-6**
28. Sattar, SP; Ahmed, S; Madison, JK; Olsen, DR; Bhatia, SC; Ellahi, S; Majeed, F; Petty, F; **Wilson, DR. *When taking medications is a sin: Patient and physician attitudes to using medications with ingredients forbidden by religious beliefs: A pilot study.* Annals of Pharmacotherapy, 2004; 38(11):1830-1835**

29. Padala, P; Sharma, A; Petty, F; **Wilson, DR**. *Methohexital, etomidate and propofol in electro-convulsive therapy (ECT): Are differences real in the elderly?* Journal of ECT 20(1):56-66, 2004
30. **Wilson, DR**; Malin, PJ; Ramaswamy, S. *Treatment of bipolar disorder in the presence of common medical conditions.* Current Psychiatry (Suppl) Feb, 2005, pp. 1-10.
31. **Wilson, DR**. *The seven deadly sins of an academic chair.* Academic Psychiatry 30(4):304-308, 2006
32. Padala, P; Ramaswamy, S; Madison, K; Monnahan, M; Marcil, W; Price, P; Uddin, A; **Wilson, DR**; Petty, F. *Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women.* International Clinical Psychopharmacology, 2006; 21:275–80
32. **Wilson, DR**. *The evolution of evolutionary epidemiology: A defense of pluralistic epigenetic modes of transmission.* Behavioral and Brain Sciences, 2006; 29(4):427-29
33. **Wilson, DR**; Price, J. *Evolutionary epidemiology of endophenotypes in the bipolar spectrum: Evolved neuropsychological mechanisms of social rank.* Current Psychosis and Therapeutics Reports, 2006, 4 (4), 176-180.
34. Price, JS; Gardner, R Jr.; **Wilson, DR**; Sloman, L; Rohde, P; Erickson, M. (2007). *Territory, rank and mental health: The history of an idea.* Evolutionary Psychology, 5(3): 531-554.
35. Kavan, M; Malin, PJ; **Wilson, DR**. *The dual role of academic psychiatry faculty in the evaluation and treatment of medical students: An ethical conundrum.* Academic Psychiatry, (in press).
36. Sattar, P; Grant, K; Petty, F; **Wilson, DR**. *A comparison of antipsychotic polypharmacy practices across public mental health settings.* Psychiatric Services, (in press).
37. Ramaswamy, S; Mattai, A; **Wilson, DR**. *Modafinil: What does the evidence tell us?* Current Psychiatry, (in press).
38. Romanowicz M, Ramaswamy S, **Wilson DR**. *Hyponatremia in a 64-year-old woman.* Current Psychiatry, (in press).
39. Sattar, P; Grant, K; Petty, F; **Wilson, DR**. *A comparison of antipsychotic polypharmacy practices across public mental health settings.* Psychiatric Services, (in press)

**C. Research Support.** List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

#### **FEDERAL, Currently or Recently Funded**

##### **Principal Investigator:**

1. NIMH: *Relapse Prevention: Oral v. Long Acting 2<sup>nd</sup> Generation Antipsychotic Medication* (2006-2011, \$960,000; resubmission: recommended at the 6<sup>th</sup> percentile with a priority score of 160; final NIMH Council Review, 4.05; funded 3.06)
2. NIMH: *Ethnicity & the Diagnosis of Affective Illness* (2005-2009, \$229,045; Co-PI with S. Strakowski, PI, University of Cincinnati; funded at the 4<sup>th</sup> percentile)
3. CIES: Fulbright Research Award #5407 Egypt-USA Research Exchange: *Pharmacotherapy & Psychotherapy of PTSD: Congruences & Differences in Egypt & America* (2005-06, up to \$65,000; "Recommended", pending final letter of approval of the USA-Egypt Commission for Educational & Cultural Exchange, 3.05; informally carried out in interim)

##### **Co-Investigator or Consultant:**

4. HHS: *Compassion Demonstration Project: Nebraskans Expanding Behavioral Health Access through Network Delivery Systems* (2003-2006, \$3,700,742; A. Thomkins, PI, UN-L)
5. HHS: Health Resources and Services Administration: *Center of Excellence for Disparities in Healthcare*. (\$1,875,000; Sade Kosoko-Laski, MD, PI, Creighton University)
6. NIMH: *Nebraska NIMH Outreach Partnership of the Nebraska Association of Behavioral Health Organizations (NABHO)*. (2005-2009, \$75,000; P. Connell, MSN, PI, Boys Town National Research Hospital [BTNRH])
7. NIH: NIDA: *Center of Excellence at Creighton University: Development of an Assessment and Training Resource for Medical Students and Primary Care Residents to Advance the Prevention, Diagnosis and Treatment of Methamphetamine Abuse/Dependence* (12.2006, \$50,000; Pirzada Sattar, M.D., PI, Creighton, letter of award 1.07)

#### **STATE & FOUNDATION GRANTS, Currently or Recently Funded**

##### **Principal Investigator:**

- |     |  |           |             |             |
|-----|--|-----------|-------------|-------------|
| 12. | Health Future Foundation<br>Clinical Neuroscience Research Development         | Creighton | Wilson [PI] | 01/01-01/04 |
| 13. | Health Future Foundation<br>Neuroscience Laboratory Infrastructure Development | Creighton | Wilson [PI] | 01/01-01/04 |

##### **Co-Investigator:**

- |     |   |           |                |       |
|-----|---|-----------|----------------|-------|
| 14. | Health Future Foundation<br>Antipsychotic: Hyperleptinemia, bone mineral density & metabolism in men and premenopausal women with schizophrenia.            | Creighton | Ramaswamy [PI] | 8/06- |
| 15. | State of Nebraska LB692<br>University Tobacco Settlement Biomedical Research Development Fund: Program & Infrastructure for Violence and Behavior Research. | Creighton | Sullivan [PI]  | 7/04- |

**INDUSTRY-SPONSORED GRANTS, Currently or Recently Funded****Principal Investigator:**

Solvay Pharmaceutical	Creighton	Wilson [PI]	10/07-
<i>Bifeprunox® v. Quetiapine: Weight changes in stable schizophrenic patients. A randomized, multicenter, double-blind, placebo-controlled study.</i>			
Eli Lilly & Company	Creighton	Wilson [PI]	09/03-
<i>Efficacy of high dose olanzapine in controlled, fixed dose-responsive trial for the treatment of psychoses</i>			

**Co-Investigator:**

AstraZeneca	Creighton	Sattar [PI]	09/05-
<i>Seroquel® v. Risperidone: Co-morbid psychosis &amp; cocaine and/or amphetamine misuse.</i>			
Abbott	Creighton	Sattar [PI]	11/05-
<i>Depakote ER®: Comorbid mania &amp; substance abuse.</i>			
Novartis	Creighton	Bhatia [PI]	07/06-
<i>XBD173: Safety, efficacy &amp; tolerability in GAD.</i>			
Wyeth Research	Creighton	Bhatia [PI]	07/03 – 07/05
<i>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 in Adult Outpatients with Major Depressive Disorder</i>			
Forest Laboratories	Creighton	Bhatia [PI]	12/02 – 12/04
<i>A double-blind, placebo-controlled evaluation of safety and efficacy of escitalopram in pediatric depression.</i>			
Janssen Pharmaceutica	Creighton	Petty [PI]	06/01 – 06/04
<i>Risperidone for Women with Posttraumatic Stress Syndrome due to Domestic Violence or Rape</i>			
Ortho-McNeil Pharmaceutical	Creighton	Petty [PI]	11/01 – 6/04
<i>CAPSS – 201</i>			
<i>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians</i>			
Pfizer	Creighton	Petty [PI]	11/01 – 11/04
<i>Geodon Therapy for Posttraumatic Stress Disorder</i>			
Pfizer	Creighton	Petty [PI]	06/02 – 06/04
<i>Zoloft Therapy for Posttraumatic Stress Disorder in Veterans</i>			

**OTHER COMPLETED STUDIES:****Principal Investigator:**

Antipsychotics:	<i>Metabolic effects, Lilly</i>	Creighton University
Olanzapine v. risperidone:	<i>Treatment-resistant schizophrenia, Lilly</i>	ODMH & Creighton University
Olanzapine v. divalproex:	<i>Acute mania, Lilly</i>	ODMH
Atypical antipsychotics:	<i>Glycemia, diabetes &amp; ketoacidosis</i>	ODMH
Informed Consent:	<i>Major psychotropics</i>	ODMH & Ohio Attorney General
Olanzapine:	<i>Prolactin response, Janssen</i>	ODMH
Venlafaxine ER:	<i>Post-traumatic stress disorder, Wyeth</i>	Creighton University

**Co-Investigator:**

Olanzapine:	<i>Geriatric psychoses</i>	Ohio Department of Mental Health
Venlafaxine ER:	<i>Adolescent social anxiety, Wyeth</i>	Creighton University
Risperidone:	<i>PTSD (non-combat), Janssen</i>	Creighton University
Venlafaxine ER:	<i>Adolescent panic anxiety, Wyeth</i>	Creighton University
Topiramate:	<i>PTSD women (non-combat), Ortho</i>	Creighton University
Sertraline:	<i>PTSD, Pfizer Pharmaceuticals</i>	Creighton University
Ziprasidone:	<i>PTSD, Pfizer Pharmaceuticals</i>	Creighton University
Deramciclone:	<i>GAD, Pharmacia &amp; Upjohn</i>	Creighton University
Venlafaxine ER:	<i>Panic, Wyeth</i>	Creighton University
Quetiapine:	<i>Substance abuse, Astra-Zeneca</i>	Creighton University
Olanzapine v. Divalproex:	<i>Bipolar, Lilly</i>	Creighton University